APHOMS is a randomized, controlled, openlabel study evaluating the safety & efficacy of extracorporeal photopheresis (ECP) in the treatment of secondary Multiple Sclerosis. In 2021, ADSCC received approval from the DOH to provide in-house treatment using Extracorporeal Photopheresis (ECP) which conveys immunomodulatory effects and has been effectively used to treat conditions which are similar to Multiple Sclerosis (MS) characteristics. A total of 45 participants are estimated to enroll with an estimated start date for January 2022.


In 2021, ADSCC completed the protocol for OPERA, a randomized, controlled, open-label study evaluating the efficacy of extracorporeal photopheresis (ECP) in the treatment of Type 1 Diabetes Mellitus. A total of 40 participants are estimated to enroll with a total study duration of 1.5 years.

Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

ADSCC aims to introduce and provide a standard of care for relapsing-remitting multiple sclerosis patients using autologous hematopoietic stem cell transplantation (AHSCT). The primary objective is to selectively reprogram the adaptive immune system, restore homeostasis and permanently eliminate pathogenic clones that drive autoimmune inflammation and tissue destruction

FBM-01 Protocol

ADSCC researchers are pursuing FBM-01© to cover the treatment of autoimmune diseases including MS, that combines the use of stem cells and ECP. The treatment relies on the use of an advanced technology with a unique protocol to evaluate the safety and efficacy of the procedure while helping better understand the disease in question.

CAR-T Cells

ADSCC will be the first in the region to locally engineer and test CAR-T cells for their effectiveness in treating different forms of cancer. This includes a type of treatment in which a patient’s T-cells (a type of immune cell) are modified to target cancer cells.